Skip to main content
WANBANGDE PHARMACEUTICAL HOLDING GROUP CO.,LTD. logo

WANBANGDE PHARMACEUTICAL HOLDING GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 002082 ISIN · CNE000001P94 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,871 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002082

About WANBANGDE PHARMACEUTICAL HOLDING GROUP CO.,LTD.

https://www.wepon.com.cn

Wanbangde Pharmaceutical Holding Group Co., Ltd. specializes in the research, development, manufacturing, and distribution of pharmaceutical products and medical devices. The company's pharmaceutical portfolio focuses on cardiovascular and cerebrovascular treatments, nervous system medications, and respiratory drugs, with a particular emphasis on natural plant-based medicines and standardized traditional Chinese medicine extracts, such as Ginkgo biloba preparations. In the medical device sector, the group produces orthopedic implants, surgical instruments, and medical consumables. By maintaining a vertically integrated supply chain that spans from raw material cultivation to finished dosage forms, the company ensures rigorous quality control across its operations. Its research and development strategy prioritizes the modernization of traditional therapies and the advancement of innovative drug delivery systems to address chronic disease management and surgical needs.

Recent filings

Filing Released Lang Actions
关于股票交易异常波动的公告
Regulatory Filings Classification · 90% confidence The document is a public announcement by the company concerning abnormal stock price fluctuations and the company’s investigation and disclosures under Shenzhen Stock Exchange rules. It is not a financial report, earnings release, management discussion, or share issuance notice but a regulatory announcement addressing trading irregularities and risk warnings. This fits the catch-all “Regulatory Filings” category.
2026-05-25 Chinese
关于股票交易异常波动暨严重异常波动的公告
Regulatory Filings Classification · 85% confidence The document is an official announcement by a listed company regarding abnormal and serious abnormal stock price fluctuations, explaining investigations, risk warnings, and compliance with exchange rules. It is not a financial report, earnings release, board change, share issue, or dividend notice. It falls under general regulatory / compliance announcements that don’t fit more specific categories. Hence it should be classified as a Regulatory Filing (RNS).
2026-05-20 Chinese
关于子公司取得授予发明专利权通知书的公告
Regulatory Filings Classification · 85% confidence The document is an announcement by a listed company about its subsidiary receiving a patent grant notice from the national IP office. It is neither a financial report nor a statutory corporate disclosure type like dividends, share issues, or AGM materials. It represents a general regulatory announcement regarding intellectual property rights, fitting the catch-all category of Regulatory Filings (RNS).
2026-05-18 Chinese
回购股份报告书
Transaction in Own Shares Classification · 98% confidence The document is a detailed report on a planned share buyback (“回购股份报告书”), outlining the type, amount, price, purpose, funding source, procedures, timelines, and risk factors for the company’s repurchase of its own A-share stock. This matches the ‘Transaction in Own Shares’ category (share repurchase report).
2026-05-18 Chinese
关于股票交易异常波动的公告
Regulatory Filings Classification · 92% confidence The document is a stock exchange announcement titled “关于股票交易异常波动的公告,” detailing an investigation and disclosures required under Shenzhen Stock Exchange rules regarding abnormal trading fluctuations. It contains no financial statements or report attachments, but is a mandatory regulatory disclosure of unusual stock price movements. This does not fit any specific financial report category (e.g., 10-K, IR, ER) and is best classified as a general regulatory filing.
2026-05-17 Chinese
关于回购公司股份的方案
Transaction in Own Shares Classification · 92% confidence The document is a formal corporate announcement detailing the company’s share buyback (repurchase) plan, including the purpose, amount, price range, timeline, and board authorizations. It outlines the repurchase mechanics and regulatory compliance for buying back its own shares. This matches the definition for Transaction in Own Shares (share repurchase) under Code: POS.
2026-05-15 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.